Novocure's Optune Lua® has received approval in Japan for the treatment of unresectable advanced/recurrent non-small cell lung cancer (NSCLC).
The approval allows concurrent use of Optune Lua with PD-1/PD-L1 inhibitors for adult patients who have progressed on or after platinum-based chemotherapy.
The Ministry of Health, Labour and Welfare approval is based on the results of the Phase 3 LUNAR trial, showing significant improvement in median overall survival in NSCLC patients treated with Optune Lua.
Ministry Approval in Japan
Optune Lua approved for use with PD-1/PD-L1 inhibitors in adult NSCLC patients post platinum-based chemotherapy.
Phase 3 LUNAR Trial Results
Statistically significant improvement in median overall survival rates with Optune Lua treatment.
Device Description
Optune Lua is a wearable medical device delivering Tumor Treating Fields for cancer cell death.
- The approval opens up a new treatment option for advanced NSCLC patients in Japan.
- Patients treated with Optune Lua concurrently with PD-1/PD-L1 inhibitors showed a 3.3-month extension in median overall survival compared to the control group.
- Device-related adverse events were mostly low grade, indicating a manageable safety profile for Optune Lua.
The approval of Optune Lua in Japan marks a significant milestone in the treatment of NSCLC, offering hope to patients facing this aggressive disease. Novocure's focus on innovative therapies continues to make a positive impact on cancer treatment worldwide.